(4-bromophenyl)(2-chlorophenyl)methanol | 464190-32-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-bromophenyl)(2-chlorophenyl)methanol
• 英文别名: (4-Bromo-phenyl)-(2-chloro-phenyl)-methanol；(4-bromophenyl)-(2-chlorophenyl)methanol
• CAS: 464190-32-7
• 化学式: C₁₃H₁₀BrClO
• 分子量: 297.579
• InChiKey: MNGFSRMAUKKHHU-UHFFFAOYSA-N

物化性质

• 沸点：
  406.4±35.0 °C(Predicted)
• 密度：
  1.524±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (4-bromophenyl)(2-chlorophenyl)methanol 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 生成 1-Bromo-4-[chloro-(2-chlorophenyl)methyl]benzene
  参考文献：
  名称：

  Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands

  摘要：

  After the CB1 receptor antagonist SR141716 (rimonabant) was previously reported to modulate food intake, CB1 antagonism has been considered as a new therapeutic target for the treatment of obesity. Several series of urea, carbamate, amide, sulfonamide and oxalamide derivatives based on 1-benzhydrylpiperazine scaffold were synthesized and tested for CB1 receptor binding affinity. The SAR studies to optimize the CB1 binding affinity led to the potent urea derivatives. After the additional SAR studies to optimize the substituents of diphenyl rings, the combination of 2-chlorophenyl and 4-chlorophenyl turned out to be the most potent scaffold. The CB2 binding affinity assay as well as functional assay was also conducted on these compounds. Herein we wish to introduce several novel CB1 antagonists with IC50 values less than 100 nM for the CB1 receptor binding. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.01.023
• 作为产物：
  描述：

  1,4-二溴苯 、 2-氯苯甲醛 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 4.5h， 以75%的产率得到(4-bromophenyl)(2-chlorophenyl)methanol
  参考文献：
  名称：

  化合物、有机电致发光器件以及电子装置

  摘要：

  本申请属于有机材料技术领域并提供一种具有化学式1结构的化合物：其中，Ar1、Ar2、Ar3、Ar4为H或化学式1‑1所示的基团，且Ar1、Ar2、Ar3、Ar4中至少有一个为化学式1‑1所示的基团。由于分子结构含有三芳胺基团的化合物，分子结构中含有供电子的三苯胺部分以及分子大共轭体系，因此，化合物分子具有分子内电荷转移的性质。利用此类衍生物制备的有机电致发光器件均具有较高的器件效率。与现有技术相比，本申请的有机电致发光材料具有更高的稳定性，从而延长了有机电致发光器件的寿命。另外菲类稠环衍生物对电子给体、受体分别进行结构修饰可以有效地调控材料的光物理、电化学性质，从而获得能级带隙较窄的发光层材料。本申请还提供一种有机电致发光器件和电子装置。

  公开号：

  CN111018722A

文献信息

• CuH-Catalyzed Asymmetric 1,6-Conjugate Reduction of <i>p</i>-Quinone Methides: Enantioselective Synthesis of Triarylmethanes and 1,1,2-Triarylethanes
  作者：Ting Pan、Pan Shi、Bo Chen、Da-Gang Zhou、Ya-Li Zeng、Wen-Dao Chu、Long He、Quan-Zhong Liu、Chun-An Fan

  DOI：10.1021/acs.orglett.9b02308

  日期：2019.8.16

  The first copper hydride (CuH)-catalyzed asymmetric 1,6-conjugate reduction of p-quinone methides is reported. This protocol provides a new method to access a variety of triarylmethanes and 1,1,2-triarylethanes in good yields with excellent enantioselectivities and broad functional group tolerance.

  据报道，氢化铜（CuH）首次催化了对醌甲基化物的不对称1,6-共轭还原。该协议提供了一种新方法，可以以良好的收率获得优异的对映选择性和宽泛的官能团耐受性，以获取各种三芳基甲烷和1,1,2-三芳基乙烷。
• Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1and tnf
  申请人：——

  公开号：US20040097731A1

  公开（公告）日：2004-05-20

  Compounds of formula I and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof wherein the symbols are as defined are MAP kinase inhibitors, useful pharmaceutically for treating TNF&agr; and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.

  化合物I的公式及其药用可接受和可水解酯以及其酸加成盐，其中符号如定义的那样，是MAP激酶抑制剂，可用于药物治疗TNFα和IL-1介导的疾病，如类风湿性关节炎和骨代谢疾病，例如骨质疏松症。
• Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of IL-1 and TNF
  申请人：Révész Lászlo

  公开号：US06919336B2

  公开（公告）日：2005-07-19

  Compounds of formula I and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof wherein the symbols are as defined are MAP kinase inhibitors, useful pharmaceutically for treating TNFα and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.

  式I化合物及其药学上可接受和可水解酯及其酸加成盐是MAP激酶抑制剂，可用于药学上治疗TNFα和IL-1介导的疾病，例如类风湿性关节炎和骨代谢疾病，如骨质疏松症。
• SAR of benzoylpyridines and benzophenones as p38α MAP kinase inhibitors with oral activity
  作者：Laszlo Revesz、Ernst Blum、Franco E. Di Padova、Thomas Buhl、Roland Feifel、Hermann Gram、Peter Hiestand、Ute Manning、Gerard Rucklin

  DOI：10.1016/j.bmcl.2004.03.111

  日期：2004.7

  Benzoylpyridines and benzophenones were synthesized and evaluated in vitro as p38alpha inhibitors and in vivo in several models of rheumatoid arthritis. Oral activity was found to depend upon substitution: 1,1-dimethylpropynylamine substituted benzophenone 10b (IC50: 14 nM) and pyridinoyl substituted benzimidazole 17b (IC50: 21 nM) showed highest efficacy and selectivity with ED50S of 9.5 and 8.6 mg/kg po in CIA. (C) 2004 Elsevier Ltd. All rights reserved.
• HALOGENATED AMINOBENZOPHENONES AND AMINOBENZOYLPYRIDINES AS INHIBITORS OF IL-1 AND TNF
  申请人：Novartis AG

  公开号：EP1379234B1

  公开（公告）日：2006-03-29